Kapiva raises $60 million from 360 ONE, Vertex Growth to boost R&D, brand push

Kapiva is currently operating at an annual revenue run rate (ARR) of Rs 550 crore, up from Rs 350 crore in FY25, reflecting strong consumer adoption across categories and channels

Bengaluru-based modern Ayurveda brand Kapiva has raised over $60 million (Rs 510 crore) in a Series D funding round led by 360 ONE Asset and Vertex Growth, with participation from existing investors Vertex Ventures Southeast Asia & India and 3one4 Capital, the company announced on September 29.

Moneycontrol exclusively reported in September that the company wad in talks to raise about Rs 300-330 crore (about $40 million) in an internal round to expand operations and grow its market presence.

Of the total round, 60 percent is secondary and 40 percent is primary, including $28 million (Rs 240 crore) in fresh capital. The secondary component enabled an exit for early backer Fireside Ventures.

The company plans to deploy the primary capital to strengthen research and development and manufacturing, step up brand building, and build out a health-tech ecosystem around its products.

Avendus Capital acted as the exclusive financial advisor to the company and its shareholders for the transaction.

Strong revenue growth, breakeven in sight

Kapiva is currently operating at an annual revenue run rate (ARR) of Rs 550 crore, up from Rs 350 crore in FY25, reflecting strong consumer adoption across categories and channels.

The company has delivered over 80 percent year-on-year growth for the past three years.

“We are a single digit EBITDA negative business at the moment. We are very close to breakeven and will turn EBITDA positive next quarter,” Ameve Sharma, founder of Kapiva, told Moneycontrol.

Omnichannel Ayurveda expansion

Kapiva employs more than 500 people and operates through a diversified distribution network spanning general trade, modern trade, pharmacy channels, digital marketplaces, and its own website.

Its offline reach now extends to around 40,000 stores across India.

The company’s portfolio spans categories such as sports nutrition, daily energy, diabetes, blood pressure, cholesterol, liver care, hormonal balance and daily wellness.

“We set out to build consumer trust with evidence, and not just claims. This funding represents confidence in our vision to make Ayurveda the preferred choice for holistic wellness...We are making our products accessible to consumers across channels from our own website to ecommerce and now a fast growing offline channel with a reach of about 40,000 stores,” Sharma said.

Investors back evidence-led positioning

Chetan Naik, Senior Fund Manager and Strategy Head – Technology at 360 ONE Asset, said, “Kapiva’s commitment to Scientific Ayurveda—integrating modern science with traditional formulations—has enabled them to create a differentiated product portfolio with strong consumer trust. The wellness industry is experiencing a fundamental shift toward preventive healthcare, and Kapiva’s evidence-based approach focusing on diabetes, hypertension, energy, liver function and other chronic use cases sets them apart.”

James Lee, General Partner at Vertex Growth Fund, said, “India's wellness heritage has global appeal. Kapiva modernises Ayurveda by taking a scientifically-driven and research-based approach to product development and formulations. We are excited to support Kapiva team’s vision of making clinically validated Ayurvedic products, already leading in categories like diabetes care and fitness, accessible to consumers worldwide.”

Health-tech bets ahead

Kapiva said it will invest in building health-tech capabilities to make Ayurveda-driven healthcare more accessible and personalised.

The company aims to help consumers manage chronic conditions and improve long-term wellness through technology-led solutions integrated with its product ecosystem.